Navigation Links
Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
Date:5/20/2011

.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Our ability to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar;
  • Our ability to effectively manage our growth and our reliance on key personnel;
  • Volatility in Questcor's monthly and quarterly Acthar shipments
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
2. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
3. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
4. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
5. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
6. Questcor Pharmaceuticals Selects BDO USA as its Auditor
7. Questcor Reports 2010 Financial Results
8. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
9. Questcor Pharmaceuticals Reports Strong Finish to 2010
10. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
11. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 ... healthcare funding changes brought about by the ... both reimbursement and prescribing of pharmaceutical therapies. ... (MCOs) cover beneficiaries through new regulations and ... is occurring in the health exchanges—state-based marketplaces ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
(Date:7/31/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... BIIB - Free Report ), Gilead (Nasdaq: GILD ... Free Report ), AbbVie (NYSE: ABBV - Free Report ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... SHAWNEE, Kan., June 17, 2011 Bayer HealthCare LLC ... of the lawsuit between Bayer and Farnam Companies Inc. ... tick control products.  As part of the settlement, Farnam ... Farnam,s print and online advertising campaign included claims that ...
... 17, 2011 NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank, CEO, received the ... 2011 New England Award in the Medical Devices category. ... extraordinary success in such areas as innovation, financial performance ...
Cached Medicine Technology:Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads 2NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 2NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 3NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 Niche Profit ... Adam Short that is designed to provide a blueprint for ... the attention of Shane Michaels, prompting an investigative review. ... , “What really speaks volumes about the success of the ... and strategies included in it have stayed effective even through ...
(Date:7/31/2014)... Vegas, NV (PRWEB) July 31, 2014 Hook Your ... way to get ex’s to feel emotionally hungry for their partner, ... a second chance. This little trick has been taught to ... , After a quick Hook Your Ex review , Shane ... who is suffering pain from a breakup a second chance at ...
(Date:7/31/2014)... 31, 2014 Cosmetic Town has introduced ... and doctors. Doctors will be able to verify their ... reviews , which guarantees their authenticity. This will ... site to receive information that has been verified to ... system allows Cosmetic Town to filter out fake patients ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ... Pioneer Millworks’ reclaimed wood to create a unique ... Their newest location features reclaimed barn siding ... with custom selected mixed softwoods flowing throughout the ... by Pioneer Millworks’ sister company New Energy ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2
... Dynamic Packaging and Graphical User Interface, BOCA ... AGYS ), a leading provider of innovative IT ... version of the Lodging Management System(R) (LMS) property,management ... in Austin, Texas,June 16-19., LMS v8.0 ...
... WASHINGTON, June 17 Federally Employed Women,(FEW) salutes ... the,"Federal Employees Paid Parental Leave Act of 2008" ... John Warner (R-VA), Hillary Rodham Clinton (D-NY), John,Kerry ... Richard,Durbin (D-IL) for co-sponsoring this important bill. "We ...
... Gene mutations that make cells cancerous can sometimes also ... by cancer researchers at Ohio State University shows that a ... disease more susceptible to high doses of a particular anticancer ... B clinical cooperative group study led by Dr. Clara D. ...
... PHILADELPHIA Researchers from the University of Pennsylvania School ... pathway important in stem cell and developmental biology leads ... knowledge could help develop therapies for lung-tissue repair after ... last week in advance of print publication in ...
... to the public, agency says , , TUESDAY, June 17 (HealthDay ... letters warning more than two dozen companies to stop selling ... The agency is also cautioning consumers not to buy or ... and creams, and are sold under various names on the ...
... is only a minor ... problem,- 57% are unaware that diaper rash can be accompanied ... and boys, - 59% responded "no" or were unsure when asked if there was ... between diaper rash and antibiotics, PRINCETON, N.J., June 17 ...
Cached Medicine News:Health News:Agilysys Announces Latest Version of Lodging Management System(R) (LMS) 2Health News:FEW Salutes Senator for Introducing Paid Parental Leave Bill 2Health News:Gene mutation improves leukemia drug's effect 2Health News:Penn researchers find key developmental pathway activates lung stem cells 2Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 2Health News:FDA Warns Companies to Stop Selling Fake Cancer Cures 3Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 2Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 3Health News:Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment 4
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
Donor Screen & Confirmation Kit...
... This SIGNET anti-PSA antibody gives ... all cases of benign hyperplasia. In ... intense staining and 34% give definite ... only a minority of cells; this ...
Medicine Products: